Base Therapeutics
Shanghai, China · Founded 2021 · $15.4M raised
- Headquarters
- Shanghai
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- basetherapeutics.com
- Total Funding
- $15.4M
- Last Round
- $15.4M Series ASep 2024
- Rounds
- 2
About
Base Therapeutics is a Shanghai-based biotechnology company specializing in gene editing and cell-based therapies for cancer treatment. Founded in April 2021, the company develops first-in-class BASE-NK and BEAT-CART cell therapy pipelines using its proprietary AccuBase cytosine base editor platform, as well as in vivo base editing programs. In 2024, Base Therapeutics achieved a milestone as the world's first company to receive IND approval in both China and the United States for a base-edited NK cell therapy.
Summary
Base Therapeutics is a Biotech company based in Shanghai, China, founded in 2021. It has raised $15.4M in total across 2 rounds, most recently a $15.4M Series A round in Sep 2024. Investors include Gobi Partners and Baidu Ventures.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...